Cargando…
Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419935/ https://www.ncbi.nlm.nih.gov/pubmed/34488774 http://dx.doi.org/10.1186/s12934-021-01658-4 |
_version_ | 1783748858265731072 |
---|---|
author | Banerjee, Sagarika Poore, Matthew Gerdes, Svetlana Nedveck, Derek Lauridsen, Lene Kristensen, Heidi Thomsen Jensen, Henrik Max Byrd, Phillip M. Ouwehand, Arthur C. Patterson, Elaine Morovic, Wesley |
author_facet | Banerjee, Sagarika Poore, Matthew Gerdes, Svetlana Nedveck, Derek Lauridsen, Lene Kristensen, Heidi Thomsen Jensen, Henrik Max Byrd, Phillip M. Ouwehand, Arthur C. Patterson, Elaine Morovic, Wesley |
author_sort | Banerjee, Sagarika |
collection | PubMed |
description | BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can affect host mental health outcomes. Understanding the molecular characteristics of GABA production by microbes within the gut can offer insight to novel therapies for mental health. RESULTS: Three strains of Levilactobacillus brevis with syntenous glutamate decarboxylase (GAD) operons were evaluated for overall growth, glutamate utilization, and GABA production in typical synthetic growth media supplemented with monosodium glutamate (MSG). Levilactobacillus brevis Lbr-6108™ (Lbr-6108), formerly known as L. brevis DPC 6108, and Levilactobacillus brevis Lbr-35 ™ (Lbr-35) had similar growth profiles but differed significantly in GABA secretion and acid resistance. Lbr-6108 produced GABA early within the growth phase and produced significantly more GABA than Lbr-35 and the type strain Levilactobacillus brevis ATCC 14869 after the stationary phase. The global gene expression during GABA production at several timepoints was determined by RNA sequencing. The GAD operon, responsible for GABA production and secretion, activated in Lbr-6108 after only 6 h of fermentation and continued throughout the stationary phase. Furthermore, Lbr-6108 activated many different acid resistance mechanisms concurrently, which contribute to acid tolerance and energy production. In contrast, Lbr-35, which has a genetically similar GAD operon, including two copies of the GAD gene, showed no upregulation of the GAD operon, even when cultured with MSG. CONCLUSIONS: This study is the first to evaluate whole transcriptome changes in Levilactobacillus brevis during GABA production in different growth phases. The concurrent expression of multiple acid-resistance mechanisms reveals niche-specific metabolic functionality between common human commensals and highlights the complex regulation of GABA metabolism in this important microbial species. Furthermore, the increased and rapid GABA production of Lbr-6108 highlights the strain’s potential as a therapeutic and the overall value of screening microbes for effector molecule output. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-021-01658-4. |
format | Online Article Text |
id | pubmed-8419935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84199352021-09-09 Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains Banerjee, Sagarika Poore, Matthew Gerdes, Svetlana Nedveck, Derek Lauridsen, Lene Kristensen, Heidi Thomsen Jensen, Henrik Max Byrd, Phillip M. Ouwehand, Arthur C. Patterson, Elaine Morovic, Wesley Microb Cell Fact Research BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can affect host mental health outcomes. Understanding the molecular characteristics of GABA production by microbes within the gut can offer insight to novel therapies for mental health. RESULTS: Three strains of Levilactobacillus brevis with syntenous glutamate decarboxylase (GAD) operons were evaluated for overall growth, glutamate utilization, and GABA production in typical synthetic growth media supplemented with monosodium glutamate (MSG). Levilactobacillus brevis Lbr-6108™ (Lbr-6108), formerly known as L. brevis DPC 6108, and Levilactobacillus brevis Lbr-35 ™ (Lbr-35) had similar growth profiles but differed significantly in GABA secretion and acid resistance. Lbr-6108 produced GABA early within the growth phase and produced significantly more GABA than Lbr-35 and the type strain Levilactobacillus brevis ATCC 14869 after the stationary phase. The global gene expression during GABA production at several timepoints was determined by RNA sequencing. The GAD operon, responsible for GABA production and secretion, activated in Lbr-6108 after only 6 h of fermentation and continued throughout the stationary phase. Furthermore, Lbr-6108 activated many different acid resistance mechanisms concurrently, which contribute to acid tolerance and energy production. In contrast, Lbr-35, which has a genetically similar GAD operon, including two copies of the GAD gene, showed no upregulation of the GAD operon, even when cultured with MSG. CONCLUSIONS: This study is the first to evaluate whole transcriptome changes in Levilactobacillus brevis during GABA production in different growth phases. The concurrent expression of multiple acid-resistance mechanisms reveals niche-specific metabolic functionality between common human commensals and highlights the complex regulation of GABA metabolism in this important microbial species. Furthermore, the increased and rapid GABA production of Lbr-6108 highlights the strain’s potential as a therapeutic and the overall value of screening microbes for effector molecule output. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-021-01658-4. BioMed Central 2021-09-06 /pmc/articles/PMC8419935/ /pubmed/34488774 http://dx.doi.org/10.1186/s12934-021-01658-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Banerjee, Sagarika Poore, Matthew Gerdes, Svetlana Nedveck, Derek Lauridsen, Lene Kristensen, Heidi Thomsen Jensen, Henrik Max Byrd, Phillip M. Ouwehand, Arthur C. Patterson, Elaine Morovic, Wesley Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title | Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title_full | Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title_fullStr | Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title_full_unstemmed | Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title_short | Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains |
title_sort | transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (gaba) production in select levilactobacillus brevis strains |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419935/ https://www.ncbi.nlm.nih.gov/pubmed/34488774 http://dx.doi.org/10.1186/s12934-021-01658-4 |
work_keys_str_mv | AT banerjeesagarika transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT poorematthew transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT gerdessvetlana transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT nedveckderek transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT lauridsenlene transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT kristensenheidithomsen transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT jensenhenrikmax transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT byrdphillipm transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT ouwehandarthurc transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT pattersonelaine transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains AT morovicwesley transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains |